Accueil / Tag Archives: Contract/Agreement

Tag Archives: Contract/Agreement

AVEO Oncology and EUSA Pharma Announce TiNivo Combination Study Opt-in

Wednesday, September 20th 2017 at 11:10am UTC Exercise of Option Triggers $2.0 Million Research and Development Payment to AVEO CAMBRIDGE, Mass. & HEMEL HEMPSTEAD, England–(BUSINESS WIRE)– AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma today announced that EUSA Pharma, under its multi-territory licensing agreement with AVEO for FOTIVDA® (tivozanib), has opted into …

Plus »

GSK, AstraZeneca and Labcyte Form Alliance to Develop Acoustic Mass Spectrometry – a Novel Sample Handling Technology for MS-based Drug Discovery

Wednesday, September 20th 2017 at 11:30am UTC SAN JOSE, Calif.–(BUSINESS WIRE)– Labcyte Inc. today announced that GSK has joined its consortium with AstraZeneca to combine acoustic liquid dispensing technology from Labcyte with Mass Spectrometry (MS) for use in high throughput small molecule screening and other drug discovery applications. Acoustic liquid …

Plus »

US Medical Innovations, LLC and the George Washington University Sign a $5.3 Million Agreement to Launch a New Plasma-Based Cancer Therapy Program

Monday, September 18th 2017 at 9:03pm UTC TAKOMA PARK, Md.–(BUSINESS WIRE)– US Medical Innovations, LLC (USMI) announced today that its parent company, US Patent Innovations, LLC (USPI), announced today that USPI has signed a $5.3 million sponsored research agreement with the George Washington University (GW) in Washington, D.C. Under the …

Plus »

Eagle Pharmaceuticals Licenses Japanese Rights for Bendamustine Hydrochloride Ready-to-dilute and Rapid Infusion Injection Products to SymBio Pharmaceuticals Limited

Wednesday, September 20th 2017 at 10:50am UTC – Begins Process to Maximize Value of Eagle’s Product Portfolio Worldwide – – $12.5 Million Upfront Payment Plus Future Potential Milestones and Royalty Payments – WOODCLIFF LAKE, N.J. & TOKYO–(BUSINESS WIRE)– Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) (“Eagle” or “the Company”) and SymBio Pharmaceuticals Limited …

Plus »

Mitobridge Adds NAD+ Modulation as a Therapeutic Approach for Improving Mitochondrial Function

Monday, September 18th 2017 at 12:00pm UTC Company Licenses Intellectual Property from École polytechnique fédérale de Lausanne CAMBRIDGE, Mass.–(BUSINESS WIRE)– Mitobridge, Inc., a biopharmaceutical company pioneering the discovery and development of products that improve mitochondrial function, broadens its therapeutic approach to include Nicotinamide Adenine Dinucleotide (NAD+) pathway modulation. The company …

Plus »

Transgene: First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers

Tuesday, September 19th 2017 at 3:45pm UTC Clinical Trial in Collaboration with the Alliance between Merck KGaA, Darmstadt, Germany, and Pfizer First Results Expected in 2018 STRASBOURG, France–(BUSINESS WIRE)– Transgene (Paris:TNG), a biotech company that designs and develops viral-based immunotherapies, today announces that the first patient has been treated at …

Plus »

Synpromics Announces Gene Therapy Research Partnership with Solid Biosciences

Wednesday, September 20th 2017 at 6:30am UTC EDINBURGH, Scotland–(BUSINESS WIRE)– Synpromics Ltd, the leader in gene control, today announces a new research partnership with Solid Biosciences, LLC. Under the terms of the agreement, Synpromics will provide Solid Biosciences access to a set of key muscle-selective promoter candidates to be used …

Plus »

Arcus Biosciences Announces Option and License Agreement with Taiho Pharmaceutical Co. Ltd.

Wednesday, September 20th 2017 at 1:30am UTC HAYWARD, Calif.–(BUSINESS WIRE)– Arcus Biosciences, a US-based biotechnology company focused on the discovery and development of innovative cancer immunotherapies, announced today that it has entered into an option and license agreement with Taiho Pharmaceutical Co. Ltd., for the potential development and commercialization of …

Plus »

Alcresta Therapeutics Receives New Innovative Technology Contract from Vizient, Inc. For RELiZORB® (iMMOBILIZED LIPASE) Cartridge

Tuesday, September 19th 2017 at 6:34pm UTC WARREN, N.J.–(BUSINESS WIRE)– Alcresta Therapeutics, Inc. announced RELiZORB has received an Innovative Technology contract from Vizient, Inc. the largest member-driven health care performance improvement company in the country. The awarded contract, effective Sept. 1, 2017, was based on a recommendation of RELiZORB by …

Plus »
Macbook Pro
* Intel Core i7 (3.8GHz, 6MB cache)
* Retina Display (2880 x 1880 px)
* NVIDIA GeForce GT 750M (Iris)
* 802.11ac Wi-Fi and Bluetooth 4.0
* Thunderbolt 2 (up to 20Gb/s)
* Faster All-Flash Storage (X1)
* Long Lasting Battery (9 hours)
Vous appréciez nos informations ?
Recevez nos alertes, nos dernières actualités, suivez-nous, enregistrez-vous gratuitement, rejoignez notre communauté. Merci à vous !
Increase more than 500% of Email Subscribers!
Your Information will never be shared with any third party.
Retrouvez nous sur
Un ensemble de solutions performantes
pour assurer le continuum de vos données.
Biotech Finances
All rights reserved © Company Name, 2014
Concours Genopole Young Biotech Award
* 100 000 € pour la meilleure Biotech
* Réservé aux biotechs hors santé
* 6 mois d'hébergement gratuit
* Un accompagnement personnalisé
* Etude de marché offerte
* Expertise du projet par EY
* Et nombre d'autres avantages...